Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients

J. W. Gratama, M. M. Zutter, J. Mináróvits, M. A P Oosterveer, E. D. Thomas, G. Klein, I. Ernberg

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The expression of Epstein-Barr virus (EBV)-encoded, growth-transformation-associated proteins was studied in lymphoproliferations of 9 allogeneic bone-marrow transplant (BMT) recipients. Immunoblots of cell lysates were probed with polyspecific and monospecific antisera directed against EBNA 1, 2, 3 and 6, and the membrane protein LMP. All tumors expressed EBNA 1 and LMP. EBNA 2 was detected in the tumors of 8 patients, and EBNA 3 and 6 in the tumors of 5 patients. The LMP regulatory sequences, 5' of the LMP gene, were totally unmethylated in all 7 cases, while the coding sequences of LMP and EBNA 2 were more methylated in CpG dinucleotides. EBV-transformed lymphoblastoid cell lines (LCL) express EBNA 1 to 6 and LMP; in contrast, Burkitt lymphomas express only EBNA 1. In vitro experiments have shown that EBNA 2, 3 and LMP can generate targets for cytotoxic T cell (CTL). These combined observations are consistent with the hypothesis that the EBV-associated lymphoproliferative disease of the BMT recipients escapes CTL-mediated rejection due to the failure of host immunosurveillance rather than to the down-regulation of immunogenic EBV-encoded antigens.

Original languageEnglish
Pages (from-to)188-192
Number of pages5
JournalInternational Journal of Cancer
Volume47
Issue number2
Publication statusPublished - 1991

Fingerprint

Human Herpesvirus 4
Bone Marrow
Growth
Proteins
Bone Marrow Diseases
T-Lymphocytes
Immunologic Monitoring
Neoplasms
Transformed Cell Line
Burkitt Lymphoma
Immune Sera
Membrane Proteins
Down-Regulation
Antigens
EBV-encoded nuclear antigen 1
Transplant Recipients
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients. / Gratama, J. W.; Zutter, M. M.; Mináróvits, J.; Oosterveer, M. A P; Thomas, E. D.; Klein, G.; Ernberg, I.

In: International Journal of Cancer, Vol. 47, No. 2, 1991, p. 188-192.

Research output: Contribution to journalArticle

Gratama, J. W. ; Zutter, M. M. ; Mináróvits, J. ; Oosterveer, M. A P ; Thomas, E. D. ; Klein, G. ; Ernberg, I. / Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients. In: International Journal of Cancer. 1991 ; Vol. 47, No. 2. pp. 188-192.
@article{394e2e4a16434a3b98a5e85aeabfa30a,
title = "Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients",
abstract = "The expression of Epstein-Barr virus (EBV)-encoded, growth-transformation-associated proteins was studied in lymphoproliferations of 9 allogeneic bone-marrow transplant (BMT) recipients. Immunoblots of cell lysates were probed with polyspecific and monospecific antisera directed against EBNA 1, 2, 3 and 6, and the membrane protein LMP. All tumors expressed EBNA 1 and LMP. EBNA 2 was detected in the tumors of 8 patients, and EBNA 3 and 6 in the tumors of 5 patients. The LMP regulatory sequences, 5' of the LMP gene, were totally unmethylated in all 7 cases, while the coding sequences of LMP and EBNA 2 were more methylated in CpG dinucleotides. EBV-transformed lymphoblastoid cell lines (LCL) express EBNA 1 to 6 and LMP; in contrast, Burkitt lymphomas express only EBNA 1. In vitro experiments have shown that EBNA 2, 3 and LMP can generate targets for cytotoxic T cell (CTL). These combined observations are consistent with the hypothesis that the EBV-associated lymphoproliferative disease of the BMT recipients escapes CTL-mediated rejection due to the failure of host immunosurveillance rather than to the down-regulation of immunogenic EBV-encoded antigens.",
author = "Gratama, {J. W.} and Zutter, {M. M.} and J. Min{\'a}r{\'o}vits and Oosterveer, {M. A P} and Thomas, {E. D.} and G. Klein and I. Ernberg",
year = "1991",
language = "English",
volume = "47",
pages = "188--192",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients

AU - Gratama, J. W.

AU - Zutter, M. M.

AU - Mináróvits, J.

AU - Oosterveer, M. A P

AU - Thomas, E. D.

AU - Klein, G.

AU - Ernberg, I.

PY - 1991

Y1 - 1991

N2 - The expression of Epstein-Barr virus (EBV)-encoded, growth-transformation-associated proteins was studied in lymphoproliferations of 9 allogeneic bone-marrow transplant (BMT) recipients. Immunoblots of cell lysates were probed with polyspecific and monospecific antisera directed against EBNA 1, 2, 3 and 6, and the membrane protein LMP. All tumors expressed EBNA 1 and LMP. EBNA 2 was detected in the tumors of 8 patients, and EBNA 3 and 6 in the tumors of 5 patients. The LMP regulatory sequences, 5' of the LMP gene, were totally unmethylated in all 7 cases, while the coding sequences of LMP and EBNA 2 were more methylated in CpG dinucleotides. EBV-transformed lymphoblastoid cell lines (LCL) express EBNA 1 to 6 and LMP; in contrast, Burkitt lymphomas express only EBNA 1. In vitro experiments have shown that EBNA 2, 3 and LMP can generate targets for cytotoxic T cell (CTL). These combined observations are consistent with the hypothesis that the EBV-associated lymphoproliferative disease of the BMT recipients escapes CTL-mediated rejection due to the failure of host immunosurveillance rather than to the down-regulation of immunogenic EBV-encoded antigens.

AB - The expression of Epstein-Barr virus (EBV)-encoded, growth-transformation-associated proteins was studied in lymphoproliferations of 9 allogeneic bone-marrow transplant (BMT) recipients. Immunoblots of cell lysates were probed with polyspecific and monospecific antisera directed against EBNA 1, 2, 3 and 6, and the membrane protein LMP. All tumors expressed EBNA 1 and LMP. EBNA 2 was detected in the tumors of 8 patients, and EBNA 3 and 6 in the tumors of 5 patients. The LMP regulatory sequences, 5' of the LMP gene, were totally unmethylated in all 7 cases, while the coding sequences of LMP and EBNA 2 were more methylated in CpG dinucleotides. EBV-transformed lymphoblastoid cell lines (LCL) express EBNA 1 to 6 and LMP; in contrast, Burkitt lymphomas express only EBNA 1. In vitro experiments have shown that EBNA 2, 3 and LMP can generate targets for cytotoxic T cell (CTL). These combined observations are consistent with the hypothesis that the EBV-associated lymphoproliferative disease of the BMT recipients escapes CTL-mediated rejection due to the failure of host immunosurveillance rather than to the down-regulation of immunogenic EBV-encoded antigens.

UR - http://www.scopus.com/inward/record.url?scp=0026029532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026029532&partnerID=8YFLogxK

M3 - Article

C2 - 1846349

AN - SCOPUS:0026029532

VL - 47

SP - 188

EP - 192

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -